Citations (175)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (34)
Kazuki Orime & Yasuo Terauchi. (2020) Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 21:17, pages 2101-2114.
Read now
Read now
Vasilios G. Athyros, Konstantinos Imprialos, Konstantinos Stavropoulos, Alexandros Sahinidis & Michael Doumas. (2019) Understanding the cardiovascular risk with non-insulin antidiabetic drugs. Expert Opinion on Drug Safety 18:3, pages 241-251.
Read now
Read now
Sooyoung Shin & Hyunah Kim. (2016) The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study. Therapeutics and Clinical Risk Management 12, pages 435-444.
Read now
Read now
Simona Cernea, Avivit Cahn & Itamar Raz. (2016) Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opinion on Drug Safety 15:5, pages 697-707.
Read now
Read now
Rose Anderson, Jennifer Hayes & Jeffrey W. Stephens. (2016) Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 12:4, pages 467-473.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 25:2, pages 145-158.
Read now
Read now
Jan N. Basile. (2016) A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. Hospital Practice 44:1, pages 9-20.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
Amir Hanna, Kim A Connelly, Robert G Josse & Roger S McIntyre. (2015) The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health. Expert Review of Endocrinology & Metabolism 10:1, pages 101-114.
Read now
Read now
Hiroyuki Konya, Yuzo Yano, Satoshi Matsutani, Taku Tsunoda, Takashi Ikawa, Yoshiki Kusunoki, Toshihiro Matsuo, Masayuki Miuchi, Tomoyuki Katsuno, Tomoya Hamaguchi, Jun-ichiro Miyagawa & Mitsuyoshi Namba. (2014) Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Therapeutics and Clinical Risk Management 10, pages 547-558.
Read now
Read now
William Cook, Gianmaria Minervini, Brian Bryzinski & Boaz Hirshberg. (2014) Saxagliptin Efficacy and Safety in Patients with Type 2 Diabetes Mellitus Stratified by Cardiovascular Disease History and Cardiovascular Risk Factors: Analysis of 3 Clinical Trials. Postgraduate Medicine 126:6, pages 19-32.
Read now
Read now
Jennifer B. Green. (2014) Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox. Postgraduate Medicine 126:3, pages 190-204.
Read now
Read now
Michael H. Davidson. (2014) Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus. Postgraduate Medicine 126:3, pages 56-65.
Read now
Read now
Sheila A Doggrell & Simon B Dimmitt. (2014) Gliptins – do they increase cardiovascular risk or benefit?. Expert Opinion on Drug Safety 13:5, pages 675-680.
Read now
Read now
Karoline von Websky, Christoph Reichetzeder & Berthold Hocher. (2013) Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. Vascular Health and Risk Management 9, pages 681-694.
Read now
Read now
Carolyn F Deacon & Jens J Holst. (2013) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opinion on Pharmacotherapy 14:15, pages 2047-2058.
Read now
Read now
Sana Khan, Saba Khan, Mohammed Imran, Krishna Kolappa Pillai, Mohd Akhtar & Abul Kalam Najmi. (2013) Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus – targeting thrombogenesis. Expert Opinion on Therapeutic Targets 17:6, pages 627-639.
Read now
Read now
Robert Chilton. (2013) Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism 8:4, pages 345-349.
Read now
Read now
André J. Scheen. (2013) Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes. Postgraduate Medicine 125:3, pages 7-20.
Read now
Read now
William Cook, Brian Bryzinski, Jill Slater, Robert Frederich & Elsie Allen. (2013) Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials. Postgraduate Medicine 125:3, pages 145-154.
Read now
Read now
Stephanie Aleskow Stein, Elizabeth Mary Lamos & Stephen N Davis. (2013) A review of the efficacy and safety of oral antidiabetic drugs. Expert Opinion on Drug Safety 12:2, pages 153-175.
Read now
Read now
Shamsa Ali & Vivian Fonseca. (2013)
Saxagliptin overview: special focus on safety and adverse effects. Expert Opinion on Drug Safety 12:1, pages 103-109.
Read now
Read now
Elizabeth Mary Lamos, Stephanie Aleskow Stein & Stephen N Davis. (2012) Combination of glibenclamide–metformin HCl for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 13:17, pages 2545-2554.
Read now
Read now
Jennifer B. Green. (2012) The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety. Postgraduate Medicine 124:4, pages 54-61.
Read now
Read now
Edoardo Mannucci & Ilaria Dicembrini. (2012) Incretin-based therapies and cardiovascular risk. Current Medical Research and Opinion 28:5, pages 715-721.
Read now
Read now
Sherwyn L. Schwartz. (2012) Saxagliptin for the treatment of type 2 diabetes mellitus: Focus on recent studies. Annals of Medicine 44:2, pages 157-169.
Read now
Read now
Carolyn F Deacon & Nikolaus Marx. (2012) Potential cardiovascular effects of incretin-based therapies. Expert Review of Cardiovascular Therapy 10:3, pages 337-351.
Read now
Read now
André J Scheen. (2012)
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opinion on Drug Metabolism & Toxicology 8:3, pages 383-394.
Read now
Read now
André J Scheen. (2012) A review of gliptins in 2011. Expert Opinion on Pharmacotherapy 13:1, pages 81-99.
Read now
Read now
Caroline M Apovian. (2011) Management of diabetes across the course of disease: minimizing obesity-associated complications. Diabetes, Metabolic Syndrome and Obesity 4, pages 353-369.
Read now
Read now
Matteo Monami, Ilaria Dicembrini, Daniele Martelli & Edoardo Mannucci. (2011) Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Current Medical Research and Opinion 27:sup3, pages 57-64.
Read now
Read now
Isabelle Bourdel-Marchasson, Anja Schweizer & Sylvie Dejager. (2011) Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus. Hospital Practice 39:1, pages 7-21.
Read now
Read now
Paul S. Jellinger. (2011) Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes. Postgraduate Medicine 123:1, pages 53-65.
Read now
Read now
Antonio R Chacra. (2010) Saxagliptin for type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 3, pages 325-335.
Read now
Read now
Articles from other publishers (141)
Kunika Saini, Smriti Sharma & Yousuf Khan. (2023) DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Tarimoboere Agbalalah & Sohail Mushtaq. (2022)
Effect of vitamin D
3
supplementation on cardiometabolic disease risk among overweight/obese adult males in the UK: A pilot randomised controlled trial
. Journal of Human Nutrition and Dietetics 36:1, pages 216-225.
Crossref
Crossref
Sharon Mackin and & Gemma Currie. 2022. Diabetes Drug Notes. Diabetes Drug Notes
67
94
.
Michelangela Barbieri, Vittoria Cataldo, George T. Griffing & Giuseppe Paolisso. 2022. Pathy's Principles and Practice of Geriatric Medicine. Pathy's Principles and Practice of Geriatric Medicine
1108
1122
.
Paul Sandhu, Jann P. Ong, Vinay Garg, Mustafa Altaha, Olubenga Bello, Sewa R. Singal, Subodh Verma, Andrew T. Yan & Kim A. Connelly. (2021) The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF). Acta Diabetologica 58:5, pages 633-641.
Crossref
Crossref
Marina Rankovic, Nevena Jeremic, Ivan Srejovic, Katarina Radonjic, Aleksandra Stojanovic, Milos Glisic, Stefani Bolevich, Sergey Bolevich & Vladimir Jakovljevic. (2020) Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection. Heart Failure Reviews 26:2, pages 437-450.
Crossref
Crossref
Mohammed Altigani Abdalla, Harshal Deshmukh, Stephen Atkin & Thozhukat Sathyapalan. (2020) A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism 11, pages 204201882093830.
Crossref
Crossref
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2020. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
131
159
.
Claes Held, Harvey D. White, Ralph A.H. Stewart, Richard Davies, Shani Sampson, Karen Chiswell, Adam Silverstein, Renato D. Lopes, Ulrika Heldestad, Andrzej Budaj, Kenneth W Mahaffey & Lars Wallentin. (2019) Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. American Heart Journal 208, pages 65-73.
Crossref
Crossref
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2019. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
1
29
.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2019. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
1
29
.
Chakrapani Balijepalli, Rohan Shirali, Prashanth Kandaswamy, Anastasia Ustyugova, Egon Pfarr, Søren S. Lund & Eric Druyts. (2018) Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. Diabetes Therapy 9:4, pages 1491-1500.
Crossref
Crossref
Md. Akil Hossain & Rokeya Pervin. 2018. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome
455
473
.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2018. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
131
159
.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
29
.
Calinda K. E. Dingenouts, Wineke Bakker, Kirsten Lodder, Karien C. Wiesmeijer, Asja T. Moerkamp, Janita A. Maring, Helen M. Arthur, Anke M. Smits & Marie-José Goumans. (2017) Inhibiting DPP4 in a mouse model of HHT1 results in a shift towards regenerative macrophages and reduces fibrosis after myocardial infarction. PLOS ONE 12:12, pages e0189805.
Crossref
Crossref
Yu Hasegawa, Kenyu Hayashi, Yushin Takemoto, Cao Cheng, Koki Takane, Bowen Lin, Yoshihiro Komohara & Shokei Kim-Mitsuyama. (2017) DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Michael A. NauckJuris J. MeierMatthew A. CavenderMirna Abd El AzizDaniel J. Drucker. (2017) Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation 136:9, pages 849-870.
Crossref
Crossref
Andrew H. Briggs, Deepak L. Bhatt, Benjamin M. Scirica, Itamar Raz, Karissa M. Johnston, Shelagh M. Szabo, Klas Bergenheim, Jayanti Mukherjee, Boaz Hirshberg & Ofri Mosenzon. (2017) Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Research and Clinical Practice 130, pages 24-33.
Crossref
Crossref
Vincent Lo Re, Dena M Carbonari, M Elle Saine, Craig W Newcomb, Jason A Roy, Qing Liu, Qufei Wu, Serena Cardillo, Kevin Haynes, Stephen E Kimmel, Peter P Reese, David J Margolis, Andrea J Apter, K Rajender Reddy, Sean Hennessy, Harshvinder Bhullar, Arlene M Gallagher, Daina B Esposito & Brian L Strom. (2017) Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Research & Care 5:1, pages e000400.
Crossref
Crossref
Huang-Tz Ou, Kai-Cheng Chang, Chung-Yi Li & Jin-Shang Wu. (2017) Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes. British Journal of Clinical Pharmacology 83:7, pages 1556-1570.
Crossref
Crossref
Himika Chawla & Nikhil Tandon. (2017) Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs. American Journal of Cardiovascular Drugs 17:3, pages 203-215.
Crossref
Crossref
Pablo F. Mora & Eric L. Johnson. (2017) Cardiovascular Outcome Trials of the Incretin-Based Therapies: What Do We Know So Far?. Endocrine Practice 23:1, pages 89-99.
Crossref
Crossref
Edoardo Mannucci & Matteo Monami. (2016) Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Advances in Therapy 34:1, pages 1-40.
Crossref
Crossref
Kathrin Herrmann, Ming Zhou, Andrew Wang & Tjerk W. A. de Bruin. (2016) Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials. Clinical Diabetes and Endocrinology 2:1.
Crossref
Crossref
Byron J. Hoogwerf, A. Michael Lincoff, Angel Rodriguez, Lei Chen & Yongming Qu. (2016) Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Wlodzimierz M. Kolaczynski, Matthew Hankins, Siew H. Ong, Hartmut Richter, Andreas Clemens & Massoud Toussi. (2016) Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records. Diabetes Therapy 7:3, pages 483-496.
Crossref
Crossref
Mathew John, Ambika Gopalakrishnan Unnikrishnan, Sanjay Kalra & Tiny Nair. (2016) Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?. Indian Heart Journal 68:4, pages 564-571.
Crossref
Crossref
Alison Cameron-Vendrig, Adili Reheman, M. Ahsan Siraj, Xiaohong Ruby Xu, Yiming Wang, Xi Lei, Talat Afroze, Eric Shikatani, Omar El-Mounayri, Hossein Noyan, Ralph Weissleder, Heyu Ni & Mansoor Husain. (2016) Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. Diabetes 65:6, pages 1714-1723.
Crossref
Crossref
Tsung-Yuan Yang, Yung-Po Liaw, Jing-Yang Huang, Horng-Rong Chang, Kai-Wei Chang & Kwo-Chang Ueng. (2015) Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study. Acta Diabetologica 53:3, pages 461-468.
Crossref
Crossref
Betsy Dokken. (2016) Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition. Journal of Cardiovascular Nursing 31:3, pages 274-283.
Crossref
Crossref
M. A. Nauck, M. S. Abd El Aziz & J. J. Meier. (2016) DPP-4-Hemmer und GLP-1-Rezeptor-AgonistenDPP-4 inhibitors and GLP-1 receptor agonists. Der Diabetologe 12:3, pages 184-194.
Crossref
Crossref
Thomas Karagiannis, Eleni Bekiari, Panagiota Boura & Apostolos Tsapas. (2015) Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Therapeutic Advances in Drug Safety 7:2, pages 36-38.
Crossref
Crossref
Enzo Bonora & Massimo Cigolini. (2016) DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. Nutrition, Metabolism and Cardiovascular Diseases 26:4, pages 273-284.
Crossref
Crossref
Takayuki Mitsuhashi, Kiyoshi Hibi, Masaaki Konishi, Nobuhiko Maejima, Noriaki Iwahashi, Kengo Tsukahara, Masami Kosuge, Toshiaki Ebina, Satoshi Umemura & Kazuo Kimura. (2016) Plasma Glucagon-Like Peptide-1 and Tissue Characteristics of Coronary Plaque in Non-Diabetic Acute Coronary Syndrome Patients. Circulation Journal 80:2, pages 469-476.
Crossref
Crossref
Kim A. Connelly, Andrew Advani, Yanling Zhang, Suzanne L. Advani, Golam Kabir, Armin Abadeh, Jean-Francois Desjardins, Melissa Mitchell, Kerri Thai & Richard E. Gilbert. (2016)
Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1
α
. Journal of Diabetes 8:1, pages 63-75.
Crossref
Crossref
Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher, Thomas Seck, Sanjay Patel, Hans-Juergen Woerle & Odd Erik Johansen. (2015) Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Pavel S. Roshanov & Brittany B. Dennis. (2015) Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials. Diabetes Research and Clinical Practice 110:3, pages e13-e17.
Crossref
Crossref
Boaz Hirshberg & Arie Katz. (2015) Insights From Cardiovascular Outcome Trials with Novel Antidiabetes Agents: What Have We Learned? An Industry Perspective. Current Diabetes Reports 15:11.
Crossref
Crossref
Sohita Dhillon. (2015) Saxagliptin: A Review in Type 2 Diabetes. Drugs 75:15, pages 1783-1796.
Crossref
Crossref
Ele Ferrannini & Ralph A. DeFronzo. (2015) Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal 36:34, pages 2288-2296.
Crossref
Crossref
Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, June Ye & John J V McMurray. (2015) Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. The Lancet Diabetes & Endocrinology 3:9, pages 697-703.
Crossref
Crossref
Archana R. Sadhu, Stanley S. Schwartz & Mary E. Herman. (2015) The Rationale for use of Incretins in the Management of new Onset Diabetes After Transplantation (NODAT). Endocrine Practice 21:7, pages 814-822.
Crossref
Crossref
Jong-Mi Seong, Nam-Kyong Choi, Ju-Young Shin, Yoosoo Chang, Ye-Jee Kim, Joongyub Lee, Ju-Young Kim & Byung-Joo Park. (2015) Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study. PLOS ONE 10:5, pages e0124287.
Crossref
Crossref
Juraj Koska, Michelle Sands, Camelia Burciu & Peter Reaven. (2015) Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diabetes and Vascular Disease Research 12:3, pages 154-163.
Crossref
Crossref
M. Buysschaert, D. Amoussou-Guenou, D. Yanogo & F. Djrolo. (2015) Impact cardiovasculaire des incrétino-mimétiques chez le diabétique de type 2 : le point en 2015. Médecine des Maladies Métaboliques 9:2, pages 158-163.
Crossref
Crossref
Heba A. Ahmed, Dianne W. May, Susan C. Fagan & Lakshman Segar. (2015) Vascular Protection with Dipeptidyl Peptidase-IV inhibitors in Diabetes: Experimental and Clinical Therapeutics. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:3, pages 277-297.
Crossref
Crossref
Matthew C. Riddle. (2015) Welcome Reassurance About GLP-1 Drugs—But They Are Still Young and Not Fully Grown. Diabetes Care 38:2, pages 183-185.
Crossref
Crossref
Jang Won SonSungrae Kim. (2015) Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. Diabetes & Metabolism Journal 39:5, pages 373.
Crossref
Crossref
Wellington Santana da Silva Júnior, Amélio Fernando de Godoy-Matos & Luiz Guilherme Kraemer-Aguiar. (2015) Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?. BioMed Research International 2015, pages 1-10.
Crossref
Crossref
Joshua J. Neumiller. (2014) Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes. Clinical Diabetes 32:4, pages 170-177.
Crossref
Crossref
Patricia A. Howard. (2014) Diabetes and Cardiovascular Risk: Are Dipeptidyl Peptidase-4 Inhibitors Beneficial?. Hospital Pharmacy 49:8, pages 697-701.
Crossref
Crossref
Thomas Karagiannis, Panagiota Boura & Apostolos Tsapas. (2014) Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic Advances in Drug Safety 5:3, pages 138-146.
Crossref
Crossref
Rury R Holman, Harald Sourij & Robert M Califf. (2014) Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. The Lancet 383:9933, pages 2008-2017.
Crossref
Crossref
Andrew J. Krentz & Marcus Hompesch. (2014) Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?. Pharmaceutical Medicine 28:3, pages 109-117.
Crossref
Crossref
Alison Cameron-Vendrig, Dhanwantee Mundil & Mansoor Husain. (2014) Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors. Current Atherosclerosis Reports 16:5.
Crossref
Crossref
Ishwarlal JialalSandeep Dhindsa. (2014) No Benefit of Saxagliptin on Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Potential Explanations. Metabolic Syndrome and Related Disorders 12:3, pages 157-158.
Crossref
Crossref
L. Masmiquel. (2014) Efectos cardiovasculares y seguridad de los fármacos hipoglucemiantes: situación actual. SEMERGEN - Medicina de Familia 40:2, pages 80-88.
Crossref
Crossref
Katherine A. Lyseng-Williamson & Lily P. H. Yang. (2014) Saxagliptin: a guide to its use in type 2 diabetes mellitus. Drugs & Therapy Perspectives 30:3, pages 92-99.
Crossref
Crossref
Nayyar Iqbal, Artist Parker, Robert Frederich, Mark Donovan & Boaz Hirshberg. (2014) Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovascular Diabetology 13:1, pages 33.
Crossref
Crossref
D. Wu, L. Li & C. Liu. (2014) Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes, Obesity and Metabolism 16:1, pages 30-37.
Crossref
Crossref
Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf & Rury R. Holman. (2013) Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. American Heart Journal 166:6, pages 983-989.e7.
Crossref
Crossref
David Kountz. (2013) The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups. Advances in Therapy 30:12, pages 1067-1085.
Crossref
Crossref
Reema Abu Khalaf, Ghassan Abu Sheikha, Mahmoud Al-Sha'er & Mutasem Taha. (2013) Design, Synthesis and Biological Evaluation of N4-Sulfonamido-Succinamic, Phthalamic, Acrylic and Benzoyl Acetic Acid Derivatives as Potential DPP IV Inhibitors. The Open Medicinal Chemistry Journal 7:1, pages 39-48.
Crossref
Crossref
Lyubov Chaykovska, Markus L. Alter, Karoline von Websky, Margarete Hohmann, Oleg Tsuprykov, Christoph Reichetzeder, Barbara Kutil, Robin Kraft, Thomas Klein & Berthold Hocher. (2013) Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. Journal of Hypertension 31:11, pages 2290-2299.
Crossref
Crossref
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, P. Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D. Wiviott, Elaine B. Hoffman, Matthew A. Cavender, Jacob A. Udell, Nihar R. Desai, Ofri Mosenzon, Darren K. McGuire, Kausik K. Ray, Lawrence A. Leiter & Itamar Raz. (2013) Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine 369:14, pages 1317-1326.
Crossref
Crossref
Philip D. Home. (2013) Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations. Diabetes Care 36:10, pages 3361-3367.
Crossref
Crossref
Kim Alexander Connelly, Yanling Zhang, Andrew Advani, Suzanne L. Advani, Kerri Thai, Darren A. Yuen & Richard E. Gilbert. (2013) DPP-4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes. Cardiovascular Therapeutics 31:5, pages 259-267.
Crossref
Crossref
William Harper, Maureen Clement, Ronald Goldenberg, Amir Hanna, Andrea Main, Ravi Retnakaran, Diana Sherifali, Vincent Woo & Jean-François Yale. (2013) Pharmacothérapie du diabète de type 2. Canadian Journal of Diabetes 37, pages S428-S436.
Crossref
Crossref
Andrew Advani, Antoinette Bugyei-Twum & Kim A. Connelly. (2013) Cardiovascular Effects of Incretins in Diabetes. Canadian Journal of Diabetes 37:5, pages 309-314.
Crossref
Crossref
Pitchai Balakumar & Sokkalingam A. Dhanaraj. (2013) Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials. Cellular Signalling 25:9, pages 1799-1803.
Crossref
Crossref
M. Krempf. (2013) Étude de la saxagliptine sur la survenue d’événements cardiovasculaires chez des patients diabétiques de type 2 (étude SAVOR-TIMI 53) : description de l’étude et des patients. Médecine des Maladies Métaboliques 7:4, pages 354-359.
Crossref
Crossref
Julio Rosenstock, Nikolaus Marx, Steven E Kahn, Bernard Zinman, John J Kastelein, John M Lachin, Erich Bluhmki, Sanjay Patel, Odd-Erik Johansen & Hans-Jürgen Woerle. (2013) Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diabetes and Vascular Disease Research 10:4, pages 289-301.
Crossref
Crossref
Berthold Hocher, Yuliya Sharkovska, Michael Mark, Thomas Klein & Thiemo Pfab. (2013) The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. International Journal of Cardiology 167:1, pages 87-93.
Crossref
Crossref
O. Mosenzon, I. Raz, B. M. Scirica, B. Hirshberg, C. I. Stahre, P. G. Steg, J. Davidson, P. Ohman, D. L. Price, B. Frederich, J. A. Udell, E. Braunwald & D. L. Bhatt. (2013) Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial. Diabetes/Metabolism Research and Reviews 29:5, pages 417-426.
Crossref
Crossref
Baptist Gallwitz. (2013) Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. Therapeutic Advances in Endocrinology and Metabolism 4:3, pages 95-105.
Crossref
Crossref
B. Vergès. (2013) Effets cardiovasculaires des inhibiteurs de la DPP-4. Médecine des Maladies Métaboliques 7:3, pages 251-255.
Crossref
Crossref
Anthony H. Barnett. (2013) Complementing Insulin Therapy to Achieve Glycemic Control. Advances in Therapy 30:6, pages 557-576.
Crossref
Crossref
Cassie L Boland, Michelle DeGeeter, Donald S Nuzum & Maria Tzefos. (2013) Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors. Annals of Pharmacotherapy 47:4, pages 490-505.
Crossref
Crossref
Patrick English. (2013) Insulin: standard therapy following oral hypoglycaemic failure in type 2 diabetes?. British Journal of Hospital Medicine 74:4, pages 192-197.
Crossref
Crossref
D. S. H. Bell. (2012) Combine and conquer: advantages and disadvantages of fixed‐dose combination therapy. Diabetes, Obesity and Metabolism 15:4, pages 291-300.
Crossref
Crossref
William Harper, Maureen Clement, Ronald Goldenberg, Amir Hanna, Andrea Main, Ravi Retnakaran, Diana Sherifali, Vincent Woo & Jean-François Yale. (2013) Pharmacologic Management of Type 2 Diabetes. Canadian Journal of Diabetes 37, pages S61-S68.
Crossref
Crossref
Guohua Zhao, Chet Kwon, Aiying Wang, James G. Robertson, Jovita Marcinkeviciene, Rex A. Parker, Mark S. Kirby & Lawrence G. Hamann. (2013) Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry Letters 23:6, pages 1622-1625.
Crossref
Crossref
Mariona Nadal Llover & Maria Àngels Pellicer Jacomet. (2013) Aportaciones de los nuevos fármacos para la diabetes. FMC - Formación Médica Continuada en Atención Primaria 20:3, pages 155-165.
Crossref
Crossref
David M Carty, Russell Drummond & Miles Fisher. (2013) Cardiovascular safety and DPP-4 inhibitors. Practical Diabetes 30:2, pages 78-81.
Crossref
Crossref
André J. Scheen. (2013) Cardiovascular effects of gliptins. Nature Reviews Cardiology 10:2, pages 73-84.
Crossref
Crossref
Pam R. Taub, Erin Higginbotham & Robert R. Henry. (2013) Beneficial and Detrimental Effects of Glycemic Control on Cardiovascular Disease in Type 2 Diabetes. Current Cardiology Reports 15:2.
Crossref
Crossref
Linde M. Morsink, Mark M. Smits & Michaela Diamant. (2013) Advances in Pharmacologic Therapies for Type 2 Diabetes. Current Atherosclerosis Reports 15:2.
Crossref
Crossref
Robert R. Henry. (2013) Antihyperglycemic Drug Therapy in Patients with Diabetes and Ckd: a Closer Look at Incretin-Based Therapies. Endocrine Practice 19, pages 19-22.
Crossref
Crossref
Eun-Hee Cho. (2013) Effect of DPP-4 Inhibitors on the Cardiovascular System, Cancer and Pancreatitis. The Journal of Korean Diabetes 14:3, pages 138.
Crossref
Crossref
Pegah Yousefzadeh & Xiangbing Wang. (2013) The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus. Journal of Diabetes Research 2013, pages 1-6.
Crossref
Crossref
Samar Singh, Jyoti Bhat & Ping H. Wang. (2012) Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus. Current Cardiology Reports 15:1.
Crossref
Crossref
Alexandra Kautzky-Willer & Rosa Lemmens-Gruber. 2012. Sex and Gender Differences in Pharmacology. Sex and Gender Differences in Pharmacology
307
340
.
Robert Frederich, Robert McNeill, Niklas Berglind, Douglas Fleming & Roland Chen. (2012) The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetology & Metabolic Syndrome 4:1.
Crossref
Crossref
K. Gooßen & S. Gräber. (2012) Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 14:12, pages 1061-1072.
Crossref
Crossref
Zachary Bloomgarden. (2012) Diabetes treatment: The coming paradigm shift. Journal of Diabetes 4:4, pages 315-317.
Crossref
Crossref
Veerle Matheeussen, Wolfgang Jungraithmayr & Ingrid De Meester. (2012) Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacology & Therapeutics 136:3, pages 267-282.
Crossref
Crossref
Michael H. Davidson. (2012) Cardiovascular Risk Factors in a Patient with Diabetes Mellitus and Coronary Artery Disease: Therapeutic Approaches to Improve Outcomes: Perspectives of a Preventive Cardiologist. The American Journal of Cardiology 110:9, pages 43B-49B.
Crossref
Crossref
Jared Moore & Kathleen Dungan. (2012) Glycemic Variability and Glycemic Control in the Acutely Ill Cardiac Patient. Heart Failure Clinics 8:4, pages 523-538.
Crossref
Crossref
Alan J. Garber. (2012) Postprandial Dysmetabolism and the Heart. Heart Failure Clinics 8:4, pages 563-573.
Crossref
Crossref
Richard E. Gilbert, Yanling Zhang & Darren A. Yuen. (2012) Cell Therapy for Diabetic Nephropathy: Is the Future, Now?. Seminars in Nephrology 32:5, pages 486-493.
Crossref
Crossref
M.S. Fineman, B.B. Cirincione, D. Maggs & M. Diamant. (2012) GLP‐1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, Obesity and Metabolism 14:8, pages 675-688.
Crossref
Crossref
Baptist Gallwitz, Julio Rosenstock, Thomas Rauch, Sudipta Bhattacharya, Sanjay Patel, Maximilian von Eynatten, Klaus A Dugi & Hans-Juergen Woerle. (2012) 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet 380:9840, pages 475-483.
Crossref
Crossref
F. Vittone, A. Liberman, D. Vasic, R. Ostertag, M. Esser, D. Walcher, A. Ludwig, N. Marx & M. Burgmaier. (2012) Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe −/− mice. Diabetologia 55:8, pages 2267-2275.
Crossref
Crossref
Philip Home. (2012) Cardiovascular Disease and Oral Agent Glucose-Lowering Therapies in the Management of Type 2 Diabetes. Diabetes Technology & Therapeutics 14:S1, pages S-33-S-42.
Crossref
Crossref
Steven G. Chrysant & George S. Chrysant. (2012) Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors. The American Journal of Cardiology 109:11, pages 1681-1685.
Crossref
Crossref
George T. Griffing. 2012. Pathy's Principles and Practice of Geriatric Medicine. Pathy's Principles and Practice of Geriatric Medicine
1241
1257
.
John R. Ussher & Daniel J. Drucker. (2012) Cardiovascular Biology of the Incretin System. Endocrine Reviews 33:2, pages 187-215.
Crossref
Crossref
Tessey Jose & Silvio E Inzucchi. (2012) Cardiovascular effects of the DPP-4 inhibitors. Diabetes and Vascular Disease Research 9:2, pages 109-116.
Crossref
Crossref
Hélène Duez, Bertrand Cariou & Bart Staels. (2012) DPP-4 inhibitors in the treatment of type 2 diabetes. Biochemical Pharmacology 83:7, pages 823-832.
Crossref
Crossref
Anthony H. STONEHOUSE, Tamara DARSOW & David G. MAGGS. (2012) Incretin-based therapies. Journal of Diabetes 4:1, pages 55-67.
Crossref
Crossref
Sten Madsbad. (2012) Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No. European Journal of Internal Medicine 23:2, pages 132-136.
Crossref
Crossref
Tomohiro Matsuhashi. (2012) Sitagliptin counteracts seasonal fluctuation of glycemic control. World Journal of Diabetes 3:6, pages 118.
Crossref
Crossref
Yoshiaki KubotaMasaaki MiyamotoGen TakagiTakeshi IkedaSonoko Kirinoki-IchikawaKotoko TanakaKyoichi Mizuno. (2012) The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes. Journal of Korean Medical Science 27:11, pages 1364.
Crossref
Crossref
Lily P.H. Yang. (2012) Saxagliptin. Drugs 72:2, pages 229-248.
Crossref
Crossref
Michael E Cobble & Robert Frederich. (2012) Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovascular Diabetology 11:1, pages 6.
Crossref
Crossref
Berthold Hocher, Christoph Reichetzeder & Markus L. Alter. (2012) Renal and Cardiac Effects of DPP-4 Inhibitors from Preclinical Development to Clinical Research. Kidney and Blood Pressure Research 36:1, pages 65-84.
Crossref
Crossref
Alberto Cordero, Iñaki Lekuona, Enrique Galve & Pilar Mazón. (2012) Novedades en hipertensión arterial y diabetes mellitus. Revista Española de Cardiología 65, pages 12-23.
Crossref
Crossref
Matteo Monami, Caterina Lamanna, Carla Maria Desideri & Edoardo Mannucci. (2011) DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis. Advances in Therapy 29:1, pages 14-25.
Crossref
Crossref
Bruce Fireman, Sengwee Toh, Melissa G. Butler, Alan S. Go, Hylton V. Joffe, David J. Graham, Jennifer C. Nelson, Gregory W. Daniel & Joe V. Selby. (2012) A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiology and Drug Safety 21, pages 282-290.
Crossref
Crossref
F. M. Keane, S. Chowdhury, T.-W. Yao, N. A. Nadvi, M. G. Gall, Y. Chen, B. Osborne, A. J. V. Ribeiro, W. B. Church, G. W. McCaughan, M. D. Gorrell & D. M. T. Yu. 2011. Proteinases as Drug Targets. Proteinases as Drug Targets
118
144
.
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Ph. Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Deborah L. Price, Roland Chen, Jacob Udell & Itamar Raz. (2011) The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. American Heart Journal 162:5, pages 818-825.e6.
Crossref
Crossref
Pleun C.M. van Poppel, Mihai G. Netea, Paul Smits & Cees J. Tack. (2011) Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes. Diabetes Care 34:9, pages 2072-2077.
Crossref
Crossref
J.-F. Gautier & J.-P. Sauvanet. (2011) Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetes. Annales d'Endocrinologie 72:4, pages 287-295.
Crossref
Crossref
Alan J. Garber. (2011) Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease. Endocrine Practice 17, pages 13-19.
Crossref
Crossref
Deanna S. Kania, Jasmine D. Gonzalvo & Zachary A. Weber. (2011) Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus. Clinical Therapeutics 33:8, pages 1005-1022.
Crossref
Crossref
Vivian A. Fonseca. (2011) Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus. The American Journal of Cardiology 108:3, pages 52B-58B.
Crossref
Crossref
Roberta Baetta & Alberto Corsini. (2011) Pharmacology of Dipeptidyl Peptidase-4 Inhibitors. Drugs 71:11, pages 1441-1467.
Crossref
Crossref
Dror Dicker. (2011) DPP-4 Inhibitors. Diabetes Care 34:Supplement_2, pages S276-S278.
Crossref
Crossref
Boaz Hirshberg & Itamar Raz. (2011) Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs. Diabetes Care 34:Supplement_2, pages S101-S106.
Crossref
Crossref
Priscilla L Hollander, Jia Li, Robert Frederich, Elsie Allen & Roland Chen. (2011) Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research 8:2, pages 125-135.
Crossref
Crossref
J. H. Martin, C. F. Deacon, M. D. Gorrell & J. B. Prins. (2011) Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience. Internal Medicine Journal 41:4, pages 299-307.
Crossref
Crossref
Daniel J Drucker & Allison B Goldfine. (2011) Cardiovascular safety and diabetes drug development. The Lancet 377:9770, pages 977-979.
Crossref
Crossref
Dhanwantee Mundil, M. Hossein Noyan-Ashraf & Mansoor Husain. (2010) The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies. Current Cardiovascular Risk Reports 5:1, pages 62-69.
Crossref
Crossref
Jay ShubrookRandall ColucciAili GuoFrank Schwartz. (2011) Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Clinical Medicine Insights: Endocrinology and Diabetes 4, pages CMED.S5114.
Crossref
Crossref
C. F. Deacon. (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism 13:1, pages 7-18.
Crossref
Crossref
P. Pedrianes Martín & P.L. de Pablos Velasco. (2010) Saxagliptina, un nuevo inhibidor de la DPP-4 en el tratamiento de la diabetes mellitus tipo 2: aspectos novedosos. Avances en Diabetología 26:6, pages 445-447.
Crossref
Crossref
B. Göke, B. Gallwitz, J. Eriksson, Å. Hellqvist & I. Gause-Nilsson. (2010) Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. International Journal of Clinical Practice 64:12, pages 1619-1631.
Crossref
Crossref
Joshua J. Neumiller & R. Keith Campbell. (2010) Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. American Journal of Health-System Pharmacy 67:18, pages 1515-1525.
Crossref
Crossref
Fernando Álvarez Guisasola. (2010) Actualización sobre la última familia de fármacos orales comercializados para el tratamiento de la diabetes tipo 2: los inhibidores de la DPP-4. Aportaciones respecto a las otras familias de antidiabéticos orales. Atención Primaria 42, pages 33-40.
Crossref
Crossref
Francisco Javier Ampudia-Blasco & Antonio Ceriello. (2010) Importancia de la variabilidad del control glucémico diario en la consecución de los objetivos de control en la diabetes mellitus tipo 2: papel de los inhibidores de la dipeptidil peptidasa 4. Medicina Clínica 135, pages 33-39.
Crossref
Crossref